MindRank Presented Clinical Update on Oral GLP-1RA MDR-001 at LSX World Congress, Highlighting AI-Powered InnovationHANGZHOU, China and LONDON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, was invited to present at the 2025 LSX World Congress in Boston. The company delivered a keynote presentation entitled “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights”. This marks the first international presentation of MDR-001’s update clinical results, sparking significant interest and discussion among global industry experts and corporate leaders.
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or OverweightHANGZHOU, China and LONDON, June 24, 2025 (GLOBE NEWSWIRE) -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, today announced positive topline results from a Phase 2b clinical trial of its proprietary AI-designed oral GLP-1 receptor agonist (GLP-1RA), MDR-001, in adults with obesity or overweight in China.
